Eli Lilly (LLY)
Develops cardiometabolic, cancer, immunology, and neuroscience medicines led by tirzepatide.
$1,147.93
vs last close−16.96 (−1.46%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 84.27% | 793.31M shares | |
|---|---|---|---|
| 4,791 holders · as of Jun 30, 2026 | |||
| Insiders | 0.14% | 1.30M shares | |
| 27 holders · as of Sep 11, 2026 | |||
| Strategic holders | 5.51% | 51.89M shares | |
| 1 holder · as of Feb 11, 2022 | |||
| Other | 10.08% | 94.86M shares | |
| remainder | |||
941.36M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
4,791 holders · 793.31M shares · 423 new positions · 2,626 increased · 1,494 reduced · 160 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Lilly Endowment Inc | 90.38M | 9.60% | −1.52M | Jul 23, 2026 |
| BlackRock, Inc. | 67.54M | 7.17% | +1.16M | Aug 7, 2026 |
| Vanguard Capital Management LLC | 53.53M | 5.69% | +167.1K | Aug 13, 2026 |
| PNC Financial Services Group, Inc. | 51.32M | 5.45% | −6.2K | Aug 7, 2026 |
| State Street Corp | 36.22M | 3.85% | +605.8K | Aug 7, 2026 |
| FMR LLC | 28.46M | 3.02% | +2.12M | Aug 13, 2026 |
| Capital Research Global Investors | 20.87M | 2.22% | −3.76M | Aug 12, 2026 |
| Vanguard Portfolio Management LLC | 20.86M | 2.22% | −117.8K | Aug 13, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Lilly Endowment, Inc. | 9.70% | 91.90M | 13G | Apr 20, 2026 |
| The PNC Financial Services Group, Inc. | 5.39% | 51.15M | 13G | Feb 7, 2025 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 17, 2026 | Patrik Jonssonofficer: EVP & President, LLY Int'l | Sale | 6,500 | $1,175.10 | 54,147 |
| Aug 10, 2026 | Donald A. Zakrowskiofficer: SVP, Finance, & CAO | Sale | 2,000 | $1,185.01 | 1,526 |
| Aug 7, 2026 | Anat Hakimofficer: EVP, GC & Secretary | Sale | 5,000 | $1,190.00 | 11,875 |
| Jun 10, 2026 | Ilya Yuffaofficer: EVP&Pres, LLY USA&Global Capab | Sale | 2,500 | $1,150.77 | 29,804 |
| May 6, 2026 | Lilly Endowment Incother: Former 10% Shareholder | Sale · 2 lots | 15,828 | $995.36 | 91,881,150 |
| Jan 7, 2026 | Lilly Endowment Inc10 percent owner | Sale · 30 lots | 292,148 | $1,103.48 | 91,896,978 |
| Jan 5, 2026 | Lilly Endowment Inc10 percent owner | Sale | 1,390 | $1,085.01 | 92,189,126 |
| Dec 29, 2025 | Lilly Endowment Inc10 percent owner | Sale | 3,593 | $1,085.04 | 92,190,516 |
| Dec 23, 2025 | Lilly Endowment Inc10 percent owner | Sale | 240 | $1,085.04 | 92,196,738 |
| Dec 24, 2025 | Lilly Endowment Inc10 percent owner | Sale | 2,629 | $1,085.17 | 92,194,109 |
House and Senate disclosures
| Member | Type | Amount | Owner | Traded | Disclosed |
|---|---|---|---|---|---|
| Sen. John Boozman · AR | Sale | $1,001 – $15,000 | Joint | Nov 21, 2025 | Aug 24, 2026 |
| Rep. Michael Rulli | Sale | $1,001 – $15,000 | Jul 1, 2026 | Aug 10, 2026 | |
| Rep. Michael Rulli | Purchase | $1,001 – $15,000 | Jan 2, 2026 | Aug 10, 2026 | |
| Rep. Michael Rulli | Sale | $1,001 – $15,000 | Dec 2, 2025 | Aug 10, 2026 | |
| Sen. Tommy Tuberville · AL | Sale | $15,001 – $50,000 | Joint | Apr 15, 2025 | Aug 5, 2026 |